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Ready for a Marathon,
Not a Sprint
Renal Denervation Therapy for
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Atlanta, Georgia; and Columbus, Ohio
The recent recognition of the importance of the renal
sympathetic and somatic nerves in modulating blood pres-
sure and the development of a novel procedure that selec-
tively removes these contributors to resistant hypertension
represents an opportunity to provide meaningful beneﬁt
across a wide and varied population of hypertensive patients.
Advanced with both unbridled enthusiasm and skepticism,
performance of catheter-based interruption of the renal
efferent and afferent nerves has varied considerably across
geographies conditional to availability of clinical trials,See page 2124regulatory approval, and reimbursement. In the former
instance, the clinicaltrials.gov listing of investigations related
to renal denervation (RDN) therapy has more than doubled
in <1 year. Recognizing that treatment resistant hyperten-
sion alone may represent a market opportunity of approxi-
mately $32 billion (1), industry involvement and the
development of technology has also increased exponentially.
Presently, at least 6 technologies focusing on RDN therapy
have received European CE Mark approval, and several
more that incorporate drug delivery, intravascular and
extracorporeal ultrasound, and cryotherapy are in develop-
ment. Moreover, additional investigation is ongoing with
therapies directed toward alternative methods of reducing
sympathetic activity, independent from the renal anatomy,
including selective denervation of the carotid body and
carotid sinus, and even transureteral denervation.
Based on early phase clinical trials, catheter-based radio-
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mately 25 mm Hg and 10 mm Hg, respectively (2,3).
Overall, the results have been consistent across differing
catheter-based technologies (with most applying radio-
frequency energy), and among a limited number of indi-
viduals who had late-term (3-year) follow-up in which the
treatment effect appears durable with the maintenance of
blood pressure and pulse pressure reductions (4,5). Further,
among patients initially assigned to medical therapy alone in
a randomized trial, crossover to RDN imparts a similar
magnitude of blood pressure reduction compared with those
randomized to initial therapy. In clinical trials, the procedure
is also safe, with no compromise in homeostatic mecha-
nisms, preservation of renal function, and an acceptably low
rate of vascular complications. Pleiotropic effects related to
interruption of renal afferent activity and a dampening of
the hypersympathetic signature have been unexpectedly
observed in some instances, including improvements in
glycemic control, sleep-related apnea, diastolic heart failure,
and atrial ﬁbrillation burden (6–9).
Because of such promising results, the performance of
RDN has increased exponentially; since 2007, approximately
10,000 hypertensive patients have been treated in clinical
practice. Until results of adequately powered clinical trials
are available, restraint in clinical practice has been advocated
(10), and treatment guidelines have been proposed to limit
treatment indications (11,12). However, several populations
generally escape clinical trials; the persistent pharmacological
noncompliant patient who chooses an invasive treatment
in comparison to lifelong polypharmacy has quickly become
considered an RDN candidate. Clinical adoption of RDN
therapy has apparently exceeded the available evidence basis,
which is due in part to the inherent restrictive inclusion
criteria of clinical trials and in part to the enthusiasm of
clinicians and patients for nonpharmacologic solutions
to hypertension. Some of the targeted populations may
have lower intrinsic cardiovascular risk due to their hyper-
tension, resulting in an increased ratio of procedural risk to
beneﬁt.
Accordingly, RDN seems poised as a breakthrough
therapy that is likely to have the greatest impact on public
health than any other drug or device therapy over the next
decade, and this may continue to be the case. Yet, recall that
despite perfect results in the initial randomized trial of drug-
eluting coronary stents (13), subsequent studies and expo-
sure to real-world practice identiﬁed failures of efﬁcacy and
safety. Much like other therapies with perfect results in early
phase trials, there may be a need to level the expectations of
a treatment intended for a disease condition with no singular
etiology. For example, in less selected patient populations,
the observed reductions in blood pressure have been more
muted than the impressive declines reported in sponsored
studies (14). Furthermore, although clinical trials afﬁrm the
safety of the procedure, there also have been isolated cases of
late renal artery stenosis reported (15). Such real-world
results are difﬁcult to reconcile with randomized trials, given
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variability in medical therapy, and expansion to a broader,
less selected patient population.
Prediction of treatment response has also been elusive. In
comparative studies, up to 20% of patients may not achieve
pre-speciﬁed reductions in either 10 mmHg systolic blood
pressure (SBP) or 5 mm Hg 24-h ambulatory monitoring
(16). However, it is likely that both the magnitude of
response and responder rates to RDN in patients with
treatment resistant hypertension exceed similar metrics for
pharmaceuticals in identical populations. The temporal
course of blood pressure reduction after RDN is also highly
irregular, as incremental reductions in blood pressure have
been reported well beyond 6 months (5). In fact, the only
correlate of blood pressure reduction identiﬁed from current
clinical trials has been the degree of elevation in pre-
treatment systolic pressure. Similarly, RDN may enable
a reduction in the dose or number of antihypertensive
medications in 15% to 25% of patients, whereas dose or drug
escalation is required to improve blood pressure control in
approximately 10% to 15% (16,17).
Altogether, considering: 1) the still nascent evidence
basis for RDN; 2) an evolving understanding of the
physiology; 3) the multifactorial causes of hypertension; and
4) the infrequent but potential risks of a minimally invasive
procedure and the need to identify clinical or demographic
characteristics may provide a treatment response with
substantial clinical utility. To this purpose, the investigation
by Zuern et al. (18) reported in this issue of the Journal
offers insight into a method of predicting response to RDN
based on a surrogate measure of sympathetic overactivity.
Suppression of the cardiac baroreﬂex, a result of excessive
sympathetic signaling or direct interference from the carotid
body and chemoreﬂex, may not only underlie resistant
hypertension, but may also identify the logic of therapy
targeting the baroreﬂex. Among a limited number of
patients with treatment-resistant hypertension, pre-
procedural assessment of cardiac baroreﬂex sensitivity
(BRS) relating changes in heart rate to blood pressure was
identiﬁed in multivariable analysis as the greatest predictor
of blood pressure response at 6 months after RDN (18).
Moreover, a graded relationship that mechanistically sup-
ports the hypothesis was observed; speciﬁcally, the largest
relative reductions in systolic, diastolic, and 24-h ambula-
tory blood pressure monitoring (ABPM) were identiﬁed
among those individuals presumed to have hyper-
sympathetic activity represented by the lowest tercile of
baseline baroreﬂex sensitivity. With inclusion of other
variables in addition to BRS, the investigators propose an
interesting model to predict treatment response. Further,
BRS may more accurately identify potential response to
RDN in individuals for whom the procedural risk or the
actual cardiovascular risk of their hypertension increases the
risk to beneﬁt the balance of the invasive procedure.
Although the performance of BRS measurement is chal-
lenging, it is more practical than other methods to assess thesympathetic signature, including renal norepinephrine spill-
over sampling and recording of muscle sympathetic nerve
activity. Also, the reproducibility and accuracy of the test is
not well understood, and BRS was not uniformly predictive
for all hypertensive patients nor did it predict the magnitude
of blood pressure reduction. Importantly, BRS testing was not
performed at follow-up after RDN, a ﬁnding that would
further support the notion that reduction in sympathetic
activity with RDN permits BRS recovery, or that treatment
failures were associated with persistently high BRS activity
and therefore may not be sympathetic-mediated.
Although the study by Zuern et al. (18) demonstrates
a relationship between the blood pressure response to RDN
and prior identiﬁcation of suppressed baroreﬂex function,
the implications may extend far beyond the cautiously
narrow conclusions of the authors. First, the study intro-
duces an important unexplored mechanism that the hypo-
tensive response of RDN may be related to restoration of
baroreﬂex activity, and pre- and post-RDN testing of the
baroreﬂex in a larger cohort of treated patients is certainly
warranted to conﬁrm this relationship. Second, if the rela-
tionship is established, the potential of using baroreﬂex
testing to offer insight into the technical success of an RDN
procedure may help address the current inability to assess
adequacy of treatment and reliably predict an effect. This
potential will require fastidious prospective testing to
correlate whether the acute change in baroreﬂex parallels the
already observed long-term blood pressure response, in
addition to the technically challenging measures of total
body and renal noradrenaline spillover and muscle sympa-
thetic nerve activity (currently considered the gold standard
metrics of sympathetic function). Finally, the potential for
baroreﬂex measurement to screen ideal candidates for ther-
apeutic RDN may also be considered. Notably, the cost and
complications of RDN remain demonstrably benign com-
pared with the likely consequences of chronically elevated
blood pressure; thus, in patients with calculably high abso-
lute cardiovascular risk due to severe hypertension, screening
tests may add more task interference and expense than
clinical value. However, if RDN expands into populations
with lower inherent morbidity and mortality from hyperten-
sion, the value of such a screening test may become apparent.
An especially notable ﬁnding is that only 26 of 50 patients
(52%) in the present study were reported as responders to
RDN. However, it is important to recognize that compared
with prior reports, the investigators applied a less conven-
tional threshold for treatment response deﬁned as achieving
a 10 mm Hg or more reduction in mean SBP by ABPM.
Second, the emphasis on ABPM rather than ofﬁce SBP may
be less familiar to the large majority of practitioners who treat
hypertension. Nonetheless, not only is ABPM correlated
with sympathetic activation (19), but it is more predictive
of hypertensive end organ damage and cardiovascular
mortality than ofﬁce SBP (20–23). As a differentiator from
“white coat” or pseudo-resistant hypertension (e.g., ofﬁce
SBP>150mmHg, but ABPMSBP<135mmHg), ABPM
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RDN among true resistant hypertensive patients (17). In
contrast, RDN is not expected to reduce ABPM in pop-
ulations with “white coat” hypertension. The correlation of
changes in ofﬁce blood pressure and ABPM after therapy
likely depends, in part, on the inclusion criteria, including
a threshold ABPM.Among patients with treatment-resistant
hypertension and with SBP >160 mm Hg, reductions in
ABPM after RDN are generally more modest (approximately
one-third) than ofﬁce SBP measures. However, at lower
blood pressure levels (e.g., SBP 140 mmHg to 160 mmHg),
the correlation in ofﬁce and ABPM measures after RDN
more closely approximates a ratio of 1:1 (24,25).
Ultimately, the widespread adoption of RDN will depend
on reaching equilibrium between results of well-designed
trials, experiences in clinical practice, and the clinical reas-
surance that patient referral for the RDN procedure will be
effective, safe, and durable. Concerning the latter issue, this
is especially important given that hypertension is largely
considered as an asymptomatic disease only until end-organ
damage ensues. Therefore, although minimal standards exist
to approve and adopt selected cardiovascular device thera-
pies, the haste to expand the RDN market and introduce
new prototype technology instead requires greater time and
ﬁnancial investment in education and therapy development.
In particular, physicians from multiple disciplines and
industry collaboration will require substantial resources for
development of large-scale clinical trials that correlate blood
pressure reduction with clinical outcome and cost effec-
tiveness, awareness and education related to the beneﬁts of
hypertension treatment and RDN, and greater precision
regarding patient indications and beneﬁt. As the cumulative
experience with RDN develops, any work to identify
patients who may beneﬁt from this transformational tech-
nology should be encouraged. In this regard, the path ahead
for RDN is more akin to a marathon than a sprint, and
patients will beneﬁt most from the more costly and resource
intensive preparations for pathophysiology and indication
development than the more narrowed focus on procedural
and device iteration.Reprint requests and correspondence: Dr. David E. Kandzari,
Piedmont Heart Institute, 275 Collier Road, Suite 300, Atlanta,
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